Latinovic O - Search Results

1

HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes.

Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB. Miyauchi K, et al. Among authors: latinovic o. Cell. 2009 May 1;137(3):433-44. doi: 10.1016/j.cell.2009.02.046. Cell. 2009. PMID: 19410541 Free PMC article.

2

Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.

Heredia A, Gilliam B, Latinovic O, Le N, Bamba D, Devico A, Melikyan GB, Gallo RC, Redfield RR. Heredia A, et al. Among authors: latinovic o. Antimicrob Agents Chemother. 2007 Jul;51(7):2489-96. doi: 10.1128/AAC.01602-06. Epub 2007 May 7. Antimicrob Agents Chemother. 2007. PMID: 17485501 Free PMC article.

3

Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.

Heredia A, Latinovic O, Gallo RC, Melikyan G, Reitz M, Le N, Redfield RR. Heredia A, et al. Among authors: latinovic o. Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20476-81. doi: 10.1073/pnas.0810843106. Epub 2008 Dec 15. Proc Natl Acad Sci U S A. 2008. PMID: 19075241 Free PMC article.

4

Imaging single retrovirus entry through alternative receptor isoforms and intermediates of virus-endosome fusion.

Jha NK, Latinovic O, Martin E, Novitskiy G, Marin M, Miyauchi K, Naughton J, Young JA, Melikyan GB. Jha NK, et al. Among authors: latinovic o. PLoS Pathog. 2011 Jan 20;7(1):e1001260. doi: 10.1371/journal.ppat.1001260. PLoS Pathog. 2011. PMID: 21283788 Free PMC article.

5

Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc.

Latinovic O, Schneider K, Szmacinski H, Lakowicz JR, Heredia A, Redfield RR. Latinovic O, et al. Antiviral Res. 2014 Dec;112:80-90. doi: 10.1016/j.antiviral.2014.10.006. Epub 2014 Oct 24. Antiviral Res. 2014. PMID: 25453341 Free PMC article.

6

A novel small-molecule inhibitor of HIV-1 entry.

Heredia A, Latinovic OS, Barbault F, de Leeuw EP. Heredia A, et al. Drug Des Devel Ther. 2015 Oct 1;9:5469-78. doi: 10.2147/DDDT.S89338. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26491257 Free PMC article.

7

Identifying CCR5 coreceptor populations permissive for HIV-1 entry and productive infection: implications for in vivo studies.

Weichseldorfer M, Tagaya Y, Reitz M, DeVico AL, Latinovic OS. Weichseldorfer M, et al. Among authors: latinovic os. J Transl Med. 2022 Jan 24;20(1):39. doi: 10.1186/s12967-022-03243-8. J Transl Med. 2022. PMID: 35073923 Free PMC article.

8

CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.

Latinovic O, Reitz M, Le NM, Foulke JS, Fätkenheuer G, Lehmann C, Redfield RR, Heredia A. Latinovic O, et al. Virology. 2011 Mar 1;411(1):32-40. doi: 10.1016/j.virol.2010.12.029. Epub 2011 Jan 12. Virology. 2011. PMID: 21232779 Free PMC article.

9

Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.

Latinovic OS, Zhang J, Tagaya Y, DeVico AL, Fouts TR, Schneider K, Lakowicz JR, Heredia A, Redfield RR. Latinovic OS, et al. Curr HIV Res. 2016;14(1):24-36. doi: 10.2174/1570162x13666150909145150. Curr HIV Res. 2016. PMID: 26354735

10

Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.

Zhang Y, Du X, Liu M, Tang F, Zhang P, Ai C, Fields JK, Sundberg EJ, Latinovic OS, Devenport M, Zheng P, Liu Y. Zhang Y, et al. Cell Res. 2019 Aug;29(8):609-627. doi: 10.1038/s41422-019-0184-1. Epub 2019 Jul 2. Cell Res. 2019. PMID: 31267017 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

34 results

Search Page